M&A / Deals Adcendo secures $75m in Series C funding for ADC development Pharmaceutical TechnologyAdcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round.M&A / DealsOncologyRead full story pharminent April 15, 2026 (Last updated: April 15, 2026) Pharmaceutical Technology Adcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round. M&A / DealsOncologyRead full story Post navigation Previous: Adcendo secures $75m in Series C funding for ADC developmentNext: Lilly to acquire CrossBridge Bio for up to $300m Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
